The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2016 | Car brakes: PD-1/PD-L1 molecular pathway explained
Lieping Chen, MD, PhD of Yale School of Medicine, New Haven, CT discusses the PD-1/PD-L1 molecular pathway. The two molecules regulate immune response and control inflammation, acting similarly to a brake in a car. Cancer cells use this mechanism and amplify it to escape the immune system response and continue growing. Anti-PD-1 and anti-PD-L1 drugs developed to counteract this action are effective in 30% of solid tumors. Prof. Chen points out that further work is required to discover new treatments. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
